🚀 VC round data is live in beta, check it out!
Dianthus Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dianthus Therapeutics and similar public comparables like Anhui Anke Biotechnology, AstraZeneca Pharma India, Pfizer India, Ocular Therapeutix and more.
Dianthus Therapeutics Overview
About Dianthus Therapeutics
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Founded
2019
HQ
Employees
78
Website
Sectors
Financials (LTM)
EV
$2B
Dianthus Therapeutics Financials
Dianthus Therapeutics reported last 12-month revenue of $2M.
In the same LTM period, Dianthus Therapeutics generated $2M in gross profit and had net loss of ($172M).
Revenue (LTM)
Dianthus Therapeutics P&L
In the most recent fiscal year, Dianthus Therapeutics reported revenue of $6M and EBITDA of ($101M).
Dianthus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($101M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1627%) | XXX | XXX | XXX |
| EBIT Margin | (9623%) | XXX | (1634%) | XXX | XXX | XXX |
| Net Profit | ($172M) | XXX | ($85M) | XXX | XXX | XXX |
| Net Margin | (8775%) | XXX | (1363%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dianthus Therapeutics Stock Performance
Dianthus Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Dianthus Therapeutics' stock price is $55.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-1.97 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDianthus Therapeutics Valuation Multiples
Dianthus Therapeutics trades at 1017.4x EV/Revenue multiple, and (19.6x) EV/EBITDA.
EV / Revenue (LTM)
Dianthus Therapeutics Financial Valuation Multiples
As of March 14, 2026, Dianthus Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Dianthus Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dianthus Therapeutics has a P/E ratio of (13.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1017.4x | XXX | 319.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (19.6x) | XXX | XXX | XXX |
| EV/EBIT | (10.6x) | XXX | (19.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 1017.4x | XXX | — | XXX | XXX | XXX |
| P/E | (13.9x) | XXX | (28.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (25.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dianthus Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dianthus Therapeutics Margins & Growth Rates
Dianthus Therapeutics' revenue in the last 12 month declined by (10%).
Dianthus Therapeutics' revenue per employee in the last FY averaged $0.0M.
Dianthus Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (10%) | XXX | (67%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1627%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 112% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1841% | XXX | 401% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7907% | XXX | 1333% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1734% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dianthus Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Anhui Anke Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca Pharma India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocular Therapeutix | XXX | XXX | XXX | XXX | XXX | XXX |
| BioKangtai | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dianthus Therapeutics M&A Activity
Dianthus Therapeutics acquired XXX companies to date.
Last acquisition by Dianthus Therapeutics was on XXXXXXXX, XXXXX. Dianthus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dianthus Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDianthus Therapeutics Investment Activity
Dianthus Therapeutics invested in XXX companies to date.
Dianthus Therapeutics made its latest investment on XXXXXXXX, XXXXX. Dianthus Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dianthus Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dianthus Therapeutics
| When was Dianthus Therapeutics founded? | Dianthus Therapeutics was founded in 2019. |
| Where is Dianthus Therapeutics headquartered? | Dianthus Therapeutics is headquartered in United States. |
| How many employees does Dianthus Therapeutics have? | As of today, Dianthus Therapeutics has over 78 employees. |
| Who is the CEO of Dianthus Therapeutics? | Dianthus Therapeutics' CEO is Marino Garcia. |
| Is Dianthus Therapeutics publicly listed? | Yes, Dianthus Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Dianthus Therapeutics? | Dianthus Therapeutics trades under DNTH ticker. |
| When did Dianthus Therapeutics go public? | Dianthus Therapeutics went public in 2023. |
| Who are competitors of Dianthus Therapeutics? | Dianthus Therapeutics main competitors are Anhui Anke Biotechnology, AstraZeneca Pharma India, Pfizer India, Ocular Therapeutix. |
| What is the current market cap of Dianthus Therapeutics? | Dianthus Therapeutics' current market cap is $2B. |
| What is the current revenue of Dianthus Therapeutics? | Dianthus Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Dianthus Therapeutics? | Dianthus Therapeutics revenue growth (NTM/LTM) is (10%). |
| What is the current EV/Revenue multiple of Dianthus Therapeutics? | Current revenue multiple of Dianthus Therapeutics is 1017.4x. |
| Is Dianthus Therapeutics profitable? | No, Dianthus Therapeutics is not profitable. |
| What is the current net income of Dianthus Therapeutics? | Dianthus Therapeutics' last 12 months net income is ($172M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.